Contents

Search

cholesteryl ester transfer protein (CETP) inhibitor

Contraindications: - low HDL cholesterol Mechanism of action: - lowers LDL cholesterol - degree of LDL cholesterol lowering may not matter as much as absolute reduction in apolipoprotein B [3] - increases HDL cholesterol - no specific CETP inhibitor has had any beneficial effect on clinical outcomes, including death from cardiovascular event [1,2]* * exception may be anacetrapib (not FDA-approved as of Aug 2017) Notes: - may be more beneficial without statin [4]

Interactions

drug adverse effects of anti-hyperlipidemic agents

Related

coagulation factor Xa

Specific

anacetrapib dalcetrapib (JTT-705) torcetrapib

General

anti-hyperlipidemic agent

References

  1. Schwartz GG et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012 Nov 5 PMID: 23126252 http://www.nejm.org/doi/full/10.1056/NEJMoa1206797
  2. Keene D et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: Meta-analysis of randomised controlled trials including 117,411 patients. BMJ 2014 Jul 18; 349:g4379 PMID: 25038074
  3. Ference BA, Kastelein JJP, Ginsberg HN et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 2017 Aug 28; PMID: 28846118 http://jamanetwork.com/journals/jama/fullarticle/2650886 - Sniderman AD, Peterson ED. Genetic studies help clarify the complexities of lipid biology and treatment. JAMA 2017 Aug 28; PMID: 28846117 http://jamanetwork.com/journals/jama/fullarticle/2650885
  4. Hughes S New Lipid Hypothesis Suggests CETP Inhibitors Better Without Statins. Medscape. Sep 06, 2017. Coverage from the European Society of Cardiology Congress 2017 http://www.medscape.com/viewarticle/885191